• Manuele Morandi Guaitoli, Antonio Mazzotti, Elena Artioli, Alberto Arceri, Alberto Ruffilli, and Cesare Faldini.
• 1st Orthopaedics and Traumatology Clinic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
• Arch Orthop Trauma Surg. 2024 Dec 12; 145 (1): 1919.

BackgroundThe Coonrad-Morrey prosthesis (CMP) is a widely applied semi-constrained implant that effectively counteracts compression and thrust on the hinge. The aim of this systematic review was to evaluate the indications and outcomes of CMP across different aetiologies for which it was implanted.Materials And MethodsSelected articles were reviewed to extract: population data, surgical indications, preoperative and postoperative clinical outcomes, survival rate, and complications.ResultsA total of 873 TEAs were analysed. The majority of implants (74.8%) were in female, with a mean age of 62.8 years. Rheumatoid arthritis (RA) was the most common indication (69.9%), followed by post-traumatic sequelae (PTS) (12.1%) and acute fractures (FR) (12.1%). Improvement in functional scores were registered with a mean postoperative flexion-extension of 99.0° and a mean pronation-supination of 137.7°. A mean rate of 29.5% (range, 13.3%-71.4%) complications occurred, mechanical failure (9.04%) being the most frequent.ConclusionCMP showed favourable medium- to long-term clinical outcomes for patients with RA and FR, especially when osteosynthesis is not deemed feasible in elderly patients with low joint workload. Although CMP offered restored range of motion and functional improvements, the implant's low overall survival rate and high complication rate require careful consideration, especially in assessing individual patient factors which are then necessary to determine the suitability of CMP as a therapeutic option.© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

20 keywords...

hide…